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BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting
agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind
an aminopeptidase N overexpressed on tumour blood vessels.
METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1–3), systemic treatments
(52%; range, 1–3) or both (33%) received NGR-hTNF 0.8mgm
 2 once every 3 weeks. The primary aim of the study was
progression-free survival (PFS).
RESULTS: No grade 3–4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills
(63%). Median PFS was 2.3 months (95% CI: 1.7–2.9). A complete response ongoing after 20 months was observed in a sorafenib-
refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%)
experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months.
Median survival was 8.9 months (95% CI: 7.5–10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the
median survival was 9.5 months.
CONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.
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Hepatocellular carcinoma (HCC) ranks as the third most common
cause of cancer-related death worldwide. A majority of HCC
patients present with advanced-stage disease (class C) according to
Barcelona Clinic Liver Cancer (BCLC) classification and are
ineligible for potential radical therapy or transarterial chemo-
embolisation (Llovet et al, 2008a). Recently, sorafenib, an oral
multikinase inhibitor against vascular endothelial growth factor
receptor-2 and Ras/Raf kinase, was found to delay tumour
progression and improve survival in two large randomised trials
in patients with advanced HCC, leading to its use as first-line
treatment in this setting (Llovet et al, 2008b; Cheng et al, 2009).
Although earlier studies suggested the relevance of the Ras–Raf
pathway in primary liver tumours, more recently reported data
suggested that a major mode of action of sorafenib in the
treatment of HCC is based on its antiangiogenic potential. In fact,
hypervascularity is a prominent clinical feature of HCC and a
high microvessel density has been associated with poor prognosis,
thus rendering a vascular-targeting approach appealing for HCC
treatment (Greten et al, 2009).
Since its discovery (Carswell et al, 1975), tumour necrosis
factor-alpha (TNFa) has shown a powerful antivascular activity,
which is mainly mediated by apoptosis of tumour-associated
endothelial cells. In order to reproduce these effects, progressively
increasing doses of TNFa, given with a variety of schedules,
were tested in the early-stage clinical development. However, these
initial dose-finding studies resulted in severe toxicity when TNFa
was administered systemically, and the maximum-tolerated dose
(MTD) being 10 times lower than the estimated effective dose.
More recently, isolated limb or liver perfusion were tested as a
way by which they reach high TNFa concentrations in localised
areas. Consistently, locoregional delivery of high doses of TNFa
and chemotherapy induced elevated response rates in patients with
advanced tumours of the extremities as well as regression of
primary and metastatic liver tumours (Lejeune et al, 2006).
To exploit a ligand-directed, vascular-targeting approach, NGR-
hTNF was prepared by fusing TNFa with the tumour-homing
peptide asparagine–glycine–arginine (NGR), which is able to
selectively bind an aminopeptidase N (CD13) isoform over-
expressed by endothelial cells of many tumours, including HCC
(Arap et al, 1998; Curnis et al, 2000; Corti and Ponzoni, 2004).
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sCD13 is involved in chemokine processing, tumour invasion, and
angiogenesis, and it was shown to be crucial for pathological
development of newly formed blood vessels from pre-existing
blood vessels in a CD13-null mice model (Rangel et al, 2007).
Preclinically, murine NGR-TNF induced antitumour effects
10-fold higher than the untargeted TNFa, without evidence of
increased toxicity. It is worth noting that this conjugate showed
antitumour activity even when used at doses as low as
0.005mgkg
 1 (Curnis et al, 2002a), which is equivalent in humans
to the phase I starting dose of 0.2mgm
 2.
The MTD of NGR-hTNF when administered once every 3 weeks
was established at 45mgm
 2 in a phase I study evaluating a dose
interval from 0.2 to 60mgm
 2 (van Laarhoven et al, 2010). First-
cycle dose-limiting toxicities included transient dyspnoea and
acute infusion reaction. An additional study, further exploring the
low-dose range from 0.2 to 1.6mgm
 2, select 0.8mgm
 2 as the
optimal biological dose based on more pronounced dynamic
imaging changes, lack of TNF receptors shedding, safety, and preli-
minary antitumour activity (Gregorc et al, 2010). In this low-dose
study, tumour blood flow and perfusion as assessed by dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) were
significantly decreased. Of note, these reductions correlated with
radiologically assessed disease stabilisation, thus suggesting that
changes in tumour vascularity might be a determinant of disease
control associated with NGR-hTNF administration.
In light of both the angiogenic profile of HCC and the anti-
vascular effect of NGR-hTNF, the current phase II was designed to
assess activity and safety of NGR-hTNF given at 0.8mgm
 2 in
previously treated patients with advanced HCC.
PATIENTS AND METHODS
Eligibility criteria
Patients were required to have histologically confirmed, advanced
or metastatic HCC. Other eligibility requirements included
surgically unresectable disease; age 18 years or greater; Eastern
Cooperative Oncology Group performance status of 0–1; no more
than one previous systemic therapeutic regimen; documented
progressive disease at study entry; and adequate organ function,
including hepatic (total bilirubin o2-fold of the upper limit of
normal (ULN), transaminases o3-fold of ULN, and Child-Pugh
class-A or -B liver dysfunction with no refractory ascites or
encephalopathy), renal (serum creatinine o1.5-fold of ULN), and
haematological (absolute neutrophil count 41.5 10
9l
 1, platelets
4100 10
9l
 1). Exclusion criteria included clinically significant
cardiac disease and uncontrolled hypertension. All patients gave
written informed consent and the study was approved by the
Ethics Committees of the participating institutions.
Study design and dosing
This was a multicentre, single-agent phase II trial evaluating two
treatment schedules of NGR-hTNF in two sequential cohorts. The
primary objective of this study was to evaluate the antitumour
activity of NGR-hTNF in terms of progression-free survival (PFS),
defined as the time from baseline to the first evidence of
radiological or clinical progression, or death owing to any cause,
whichever occurred first. The date of last radiological assessment
carried out within 14 days before the first administration was
considered as baseline. Tumour restaging was conducted every
6 weeks and measurable target lesions were assessed by the
standard WHO criteria. Secondary study aims were: disease
control rate (DCR), which included the proportion of patients
experiencing complete response, partial response, or stable
disease; overall survival (OS), defined as the time from
baseline to death from any cause, or last contact; and safety, with
adverse events (AEs) graded according to the Common Termino-
logy Criteria for Adverse Events, version 3.0.
NGR-hTNF was given intravenously as an 1-h infusion at the
dose of 0.8mgm
 2 every 3 weeks (triweekly schedule). On
completion of study accrual, based on the relatively short drug
half-life and the infusion-related toxicity profile of NGR-hTNF, a
new cohort of 12 patients was enrolled to explore the safety of a
more dense dosing schedule of NGR-hTNF given at same dose of
0.8mgm
 2 on a weekly basis. This weekly schedule was considered
safe if one or fewer of six patients after a first step and two or
fewer of 12 patients had grade 4 haematological or grade 3–4
non-haematological toxicity.
The duration of the treatment was related to the clinical
outcome. In case of stable disease or objective response, the study
treatment was continued until progressive disease, unacceptable
toxicity or patient’s refusal. No formal dose reduction for
NGR-hTNF was planned. In the presence of grade 3–4 toxicity,
the treatment could be either delayed or discontinued at the
discretion of the investigator, depending on the toxicity type.
Statistical analysis
The primary end point of the study was the 12-week progression-
free rate. The sample size was based on the Simon two-stage
design, assuming a¼10%, b¼10%, P0¼35%, and P1¼60%.
Given these criteria, 16 and a total of 27 patients were to be
enrolled after the first and second stage, respectively, and study
treatment could be considered worthy of additional testing if seven
(44%) and 13 patients (48%) were progression free at 12 weeks
after the first and second stage, respectively. All efficacy analyses
were performed by using an intent-to-treat principle. Descriptive
statistics were used to characterise patients at baseline. Time-to-
event end points were estimated by Kaplan–Meier methodology.
An exploratory, univariate Cox regression model was used to
examine the impact of defined baseline characteristics on survival
time. The variables included: age (as continuous variable), gender,
PS (0 vs 1), Child-Pugh class (A vs B), BCLC stage (B vs C), Cancer
of the Liver Italian Program (CLIP) score (0–3 vs 4), and serum
alpha-fetoprotein (lower vs equal or higher than the median value).
All analyses were performed with SPSS 13.0 (SPSS Inc., Chicago,
IL, USA). ClinicalTrials.gov registration is NCT00484211.
RESULTS
Patients
Twenty-seven patients were enrolled in three centres between
February 2007 and June 2008 in the triweekly cohort. Median
patient age was 67 years (range, 34–79). From June 2008 to
February 2009, an additional 13 patients with a median age of
68 years (range, 54–78) were enrolled in a subsequent cohort treated
with NGR-hTNF given at 0.8mgm
 2 on a weekly basis. A subset of
12 patients, including five and seven patients enrolled in the
triweekly and weekly cohorts, respectively, were previously treated
with sorafenib. Patient characteristics and previous treatments for
the triweekly, weekly, and sorafenib-resistant cohorts are listed in
Table 1.
Safety
All patients received at least one dose of NGR-hTNF given every
3 weeks and resulted assessable for toxicity. A total of 99 cycles
(mean, 3.7; median, 2; range, 1–27) were delivered. Twenty-six
patients (96%) discontinued because of clinical (n¼2; Child-Pugh
progression and impaired PS) or radiological progressive disease
(n¼24), whereas one patient was on treatment at the time
these results were reported. All patients received the planned
dose on time, with the exception of three patients experiencing a
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deterioration.
Regardless of causality, most commonly experienced AEs were
chills, pain, and asthenia (Table 2). Globally, only 41 (30%) out of
all registered AEs were considered related to study drug, and the
most frequent were chills, noted over 27 cycles (27%), and
transient blood pressure increase, reported over six cycles (6%).
No grade 3–4 drug-related toxicity was observed. Among seven
patients with Child-Pugh class-B status, five (71%) experienced
grade 1–2 drug-related AEs. These events were short lived and
temporally related to study drug infusion, as they occurred
approximately 30min after the start of first infusions and lasted for
about 20min.
A total of 101 weekly cycles (range, 5–12) were delivered in the
weekly cohort. There was no exacerbation of toxicity profile by
using the weekly schedule. Neither grade 3–4 drug-related
toxicities nor toxicity-related deaths were reported. Most common
drug-related toxicity was grade 1–2 chills experienced by
10 patients (77%) over 30 infusions (30%). Eleven patients
discontinued treatment for radiological progression, one patient
for Child-Pugh progression, and one for impaired PS.
Efficacy
Overall efficacy results for the triweekly, weekly, and sorafenib-
resistant cohorts are summarised in Table 3.
Following the first study stage (n¼16) in the triweekly cohort,
five patients (31%; 95% CI: 11–59%) resulted in progression free
at the 12-week time point. Even though this proportion was lower
than the protocol-specified minimum requirement, the accrual was
restarted and also took into account the safety/tolerability profile
of the experimental drug. After the second study stage (n¼27),
eight patients (30%; 95% CI: 14–50%) were progression free at 12
weeks and the median PFS was 2.3 months (95% CI: 1.7–2.9
months).
By radiological tumour assessment, the DCR was 30%.
A complete response (4%), currently ongoing after 20 months of
therapy, was observed in a 76-year-old Child-Pugh class-B patient,
who had been previously refractory to sorafenib after 2 months of
therapy (Figure 1). A partial response (4%), with an overall 78%
tumour reduction, was reported in a 65-year-old Child-Pugh class-
B patient (Figure 2). In addition, tumour shrinkages were detected
in four out of six patients (22%) who experienced stable disease as
best response (Figure 3). This subset of eight patients who
achieved disease control received a median of five treatment cycles
(range, 4–25) and had a median PFS of 4.3 months (range, 3 to
20þ months).
At a median follow-up of 26.1 months, the median survival time
was 8.9 months (95% CI: 7.5–10.2 months), as shown in Figure 4.
The estimated survival rates at 12 and 24 months were 26 and 18%,
respectively. Five patients (18%) received subsequent anticancer
therapy (all patients were treated with sorafenib).
In post hoc subset analyses, there were no differences in survival
for patients either untreated (median, 8.6 months) or previously
treated with systemic therapy (median, 9.5 months). The subset of
Child-Pugh class-B patients (n¼7) had 6-month PFS and OS rates
of 17 and 29%, respectively.
In an univariate Cox proportional hazards model fitted by using
the baseline characteristic variables listed in Table 1, patient’s PS of 0
and CLIP scores of 0–3 were the only factors significantly associated
with improved survival (P¼0.011 and 0.048, respectively).
Paired serum samples (pre- and post-first treatment cycle)
for chromogranin A (CgA) assessments were available from
18 patients. At baseline, serum CgA levels (median, 161ngml
 1;
95% CI: 123–303) did not correlate with either PFS (Spearman’s
r¼0.10; P¼0.60) or OS (r¼0.007; P¼0.97). After the first
treatment cycle, CgA levels decreased (median, 121ngml
 1; 95%
CI: 65–212), even though the difference did not reach statistical
Table 1 Demographics, baseline characteristics, and prior treatments in
the triweekly, weekly, and sorafenib-resistant cohorts
Triweekly Weekly Sorafenib resistant
a
Characteristics N¼27 % N¼13 % N¼12 %
Sex
Male 22 82 10 77 9 75
Female 5 18 3 23 3 25
ECOG performance status
0 19 70 7 54 6 50
1 8 30 6 46 6 50
Child-Pugh class
A 20 74 13 100 11 92
B7 2 6 — — 1 8
BLCL staging
B 5 18 2 18 1 8
C2 2 8 2 1 1 8 2 1 1 9 2
CLIP score
Median 3 — 2 — 3 —
02 7 — — 1 8
12 7 1 7 2 1 6
2 9 33 6 46 3 25
3 10 37 4 31 5 42
4 4 15 2 15 1 8
Prior treatments
Transplantation 1 3 — — — —
Ablation 2 7 2 15 1 8
Resection 9 33 6 46 2 16
TACE 16 59 9 69 7 58
Systemic therapy 14 52 9 69 12 100
a-fetoprotein (ngml
 1)
Median 749 — 209 — 31 —
Mean 6409 — 14795 — 5434 —
Range 2–47031 — 2–170612 — 2–47031 —
Total bilirubin (mgdl
 1)
Median 1.1 — 1.2 — 1.0 —
Range 0.4–3.8 — 0.6–3.7 — 0.7–2.8 —
Tumour size (cm)
Median 12.4 — 6.2 — 9.6 —
Range 2.9–42.8 — 2.3–14.0 — 3.3–31.4 —
Tumour morphology
Multinodular 23 85 13 100 10 83
Uninodular 2 7 — — 1 8
No liver disease 2 7 — — 1 8
Macrovascular invasion and/or extrahepatic spread
Yes 20 74 9 69 8 67
No 7 26 4 31 4 33
Abbreviations: DFI¼disease-free interval; ECOG¼Eastern Cooperative Oncology
Group; BLCL¼Barcelona Clinic Liver Cancer; CLIP¼Cancer of the Liver
Italian Program; TACE¼transarterial chemoembolisation. Notes: Five patients
(18%, including four Child-Pugh class-B patients and one cirrhotic patient) in the
triweekly cohort and one cirrhotic patient in the weekly cohort did not previously
receive TACE or systemic therapies. Nine patients (33%) in the triweekly cohort and
six patients (46%) in the weekly cohort had previously received both TACE and
systemic therapies. Two patients (7%) in the triweekly cohort and one patient (8%)
in the weekly cohort had previously received more than one prior systemic therapies.
The DFI in the transplanted patient was 26.1 months, whereas the median DFI in
patients who underwent resection (n¼15) or ablation (n¼4) were 17.7 months
(range, 3.2–52.1) and 24.4 months (range, 3.1–47.4), respectively. There was no
correlation between the duration of DFI and the overall survival time on this study
treatment (Spearman’s r¼0.34; P¼0.14).
aIncluding five and seven patients enrolled
in the triweekly and weekly cohorts, respectively.
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sTable 2 Worst grade per patient of adverse events, irrespective of relationship to study drug, reported in the triweekly cohort
Adverse event Any grade, n (%) Grade 1, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%)
Chills 17 (63) 10 (37) 7 (26) — —
Pain 9 (33) 4 (15) 3 (11) 2 (8) —
Asthenia 8 (30) 5 (19) 3 (11) — —
Gamma-glutamyl transpeptidase increased 5 (19) — — 4 (15) 1 (4)
Oedema peripheral 5 (19) 2 (8) 3 (11) — —
Fever 5 (19) 5 (19) — — —
Hyperbilirubinaemia 4 (15) — 1 (4) 3 (11) —
Blood pressure increased 4 (15) 3 (11) 1 (4) — —
Ascites 3 (11) 1 (4) — 1 (4) 1 (4)
Constipation 3 (11) 1 (4) 2 (8) — —
Pruritus 3 (11) 2 (8) 1 (4) — —
Aspartate aminotransferase increased 2 (8) — — 2 (8) —
Diarrhoea 2 (8) 2 (8)
Dyspnoea 2 (8) 1 (4) — 1 (4) —
Hyperkalaemia 2 (8) 1 (4) 1 (4) — —
Hyperuricaemia 2 (8) 2 (8) — — —
Insomnia 2 (8) 2 (8) — — —
Nausea 2 (8) 1 (4) 1 (4) — —
Performance status decreased 2 (8) — — 2 (8) —
Anaemia 1 (4) — — — 1 (4)
Anorexia 1 (4) 1 (4) — — —
Blood uric acid increased 1 (4) 1 (4) — — —
Bundle branch block left 1 (4) 1 (4) — — —
Cholangitis 1 (4) — 1 (4) — —
Confusional state 1 (4) — — 1 (4) —
Depression 1 (4) — 1 (4) — —
Dysgeusia 1 (4) 1 (4) — — —
Dyspepsia 1 (4) — 1 (4) — —
Encephalopathy 1 (4) — 1 (4) — —
Extrasystoles 1 (4) 1 (4) — — —
Flatulence 1 (4) 1 (4) — — —
Haemoptysis 1 (4) — 1 (4) — —
Haemorrhoids 1 (4) — 1 (4) — —
Headache 1 (4) 1 (4) — — —
Hepatic cirrhosis 1 (4) — 1 (4) — —
Hepatic failure 1 (4) — — — 1 (4)
Hyperammonaemia 1 (4) — 1 (4) — —
Hyperammonaemic encephalopathy 1 (4) — — — 1 (4)
Hypotension 1 (4) 1 (4) — — —
Lymphopenia 1 (4) — — 1 (4) —
Mucosal inflammation 1 (4) 1 (4) — — —
Oesophageal varices haemorrhage 1 (4) 1 (4) — — —
Pleural effusion 1 (4) 1 (4) — — —
Pulmonary embolism 1 (4) — — — 1 (4)
Rash 1 (4) — 1 (4) — —
Sinus tachycardia 1 (4) 1 (4) — — —
Syncope 1 (4) — — 1 (4) —
Weight loss 1 (4) 1 (4) — — —
Table 3 Overall efficacy results in the triweekly, weekly, and sorafenib-resistant cohorts
Triweekly cohort (n¼27) Weekly cohort (n¼13) Sorafenib resistant (n¼12)
Best response at any time, n (%)
CR 1 (4) — 1 (8)
PR 1 (4) — —
Response rate (CR+PR) 2 (7) — 1 (8)
SD 6 (22) 5 (38) 3 (25)
Disease control rate (CR+PR+SD) 8 (30) 5 (38) 4 (33)
PD 17 (62) 8 (62) 8 (67)
Non-assessable* 2 (8) — —
PFS in all patients (months)
Median (95% CI) 2.3 (1.7–2.9) 2.0 (1.7–2.9) 2.1 (1.8–2.4)
PFS in patients with disease control
Median (95% CI) 4.3 (1.2–6.7) 3.6 (0.0–7.4) 4.3 (1.3–6.7)
OS (months)
Median (95% CI) 8.9 (7.5–10.2) NR (—) 9.5 (3.3–15.7)
Abbreviations: CI¼confidence interval; CR¼complete response; NR¼not reached; OS¼overall survival; PD¼progressive disease; PFS¼progression-free survival;
PR¼partial response; SD¼stable disease. *Two patients were withdrawn from the study before their first restaging because of symptonatic deterioration.
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ssignificance (P¼0.24, Wilcoxon test), and at this time point
tended to correlate inversely with survival (r¼ 0.44; P¼0.06).
Median survival in patients with post-first cycle CgA levels lower
and higher than the median value were 12 and 8.6 months,
respectively.
In the weekly cohort, five patients (38%) had stable disease for a
median duration of 3.6 months. After a median follow-up time of
9.0 months (95% CI: 4.7–13.3 months), the median survival has
not yet been reached. Overall, there were no apparent differences
in either tolerability or activity between the two dosing schedules,
with the triweekly administration being more preferable than
weekly for patient’s convenience.
Overall, the subset of 12 sorafenib-pretreated patients reported a
response rate of 8% and a DCR of 33%, whereas the median PFS
and survival were 2.1 and 9.5 months, respectively (Figure 5). All
patients discontinued study treatment because of radiologically
documented progressive disease. Median survival was 13 months,
if recorded from the date of sorafenib therapy initiation. The
median ratio between the PFS durations on the previous sorafenib
therapy (median, 2.3 months; 95% CI: 2.1–2.4) and on the current
study therapy (median, 2.1 months; 95% CI: 1.8–2.4) was 0.72,
with four patients (33%) experiencing PFS durations equal or
longer than those experienced while on the previous sorafenib
therapy.
CT scan February 2008 – Arterial phase – Baseline CT scan May 2008 – Arterial phase – After 4th cycle
CT scan February 2008 – Portal phase – Baseline CT scan May 2008 – Portal phase – After 4th cycle
Figure 1 Baseline and post-treatment computed tomography scans in a 76-year-old sorafenib-refractory male patient presenting with a large
(6.1 6.1cm
2) hepatic mass and extensive multifocal lesions (scans on the left), who had a complete necrosis of the primary lesion and absence of any foci
of contrast-enhancement in the remaining parenchyma (scans on the right).
Figure 2 Baseline and post-treatment computed tomography scans in a 65-year-old Child-Pugh class-B male patient presenting with a large
(10.6 8.0cm
2) hepatic mass (scan on the left), who experienced tumour shrinkage of the primary tumour after the fourth cycle of treatment (scan on
the right).
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sDISCUSSION
The patients enrolled in this study had a poor-prognosis disease as
the majority presented with BCLC C stage. The natural history of
these patients, if untreated, results in the median survival of about
6 months (Llovet et al, 2008a). Specifically, median survival times
were 4.2 months (Cheng et al, 2009) and 7.9 months (Llovet et al,
2008b) in Asian and European patient populations, respectively,
who received placebo only in two randomised phase III trials
testing sorafenib as first-line treatment of HCC.
Most patients (52%) had previously received one or more
systemic therapies and 26% did not present with a preserved
liver function (Child-Pugh class-B). Our findings indicated that
treatment with NGR-hTNF was very well tolerated. There was no
drug-related grade 3–4 toxicity, most common grade 1–2 AEs
being transient constitutional symptoms experienced by half of
patients during first infusions.
NGR-hTNF induced a confirmed response rate of 7%, a DCR of
30%, and a median survival of 8.9 months. The 3-month PFS rate
was lower than the protocol-prespecified target deemed worthy of
further testing. However, about one-third of patients remained
progression free for a median time of more than 4 months. Of note,
similar results were also observed in a subset of 12 patients
resistant/refractory to sorafenib, with a confirmed response rate of
8%, a DCR of 33%, and a median survival time of 9.5 months.
There was also evidence of the antitumour activity of NGR-hTNF
in patients either untreated or previously treated with systemic
therapy. Indeed, a sorafenib-refractory patient had a durable
complete response lasting more than 20 months and an untreated
Child-Pugh class-B patient had a partial response. These tumour
regressions in highly vascularised tumours might establish
a clinical proof-of-principle of the antivascular mode of action of
NGR-hTNF, previously documented by DCE-MRI evaluation
(Gregorc et al, 2010; van Laarhoven et al, 2010). Even though
dynamic imaging assessment was not performed in this study, it is
interesting to note the decrease, although not statistically
significant, of serum CgA levels registered after the first cycle.
Indeed, increased CgA levels, in concert with high circulating TNF-
receptor levels, have been reported as a protective factor against
TNF-induced vascular damage (Ferrero et al, 2004), as well as an
independent poor-prognosis indicator (Gregorc et al, 2007).
Historically, the design of clinical trials in HCC has been highly
challenging because of the underlying liver dysfunction. For testing
a new drug in a phase II trial, a randomised design has been
recommended as more appropriate than single-armed trial, a time-
related end point more critical than response rate, and the time to
radiological progression (TTP) more adequate than PFS, owing to
the latter representing a vulnerable composite end point in HCC
because death from cirrhosis might confound detection of
treatment effect (Llovet et al, 2008a). Therefore, the results of this
uncontrolled phase II study might only be evaluated in the context
of other trial results obtained in similar advanced-stage HCC
patients. Although comparison with historical controls is always
flawed and particularly challenging in HCC patients because of
differences in either disease stage or previous treatments, the
overall outcomes reported in this study seem to be in the range
of those reported in phase II trials testing molecular therapies
as single agents. Indeed, targeted monotherapies, mainly tested
in untreated HCC patients, were associated to response rate of
0–13%, median PFS of 1.4–6.9 months, and median survival of
6.2–13 months (Table 4), underlining the issue of patient selection
bias for uncontrolled phase II trials. The largest trials in patients
with advanced-stage HCC are the SHARP (sorafenib HCC
assessment randomised protocol) (Llovet et al, 2008b) and the
Asia-Pacific liver (Cheng et al, 2009) phase III studies evaluating
sorafenib vs placebo. Both studies enrolled previously untreated
patients. Median survival of 10.7 months and TTP of 5.5 months
were reported for sorafenib in the SHARP trial, and median
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Figure 3 Waterfall plot of changes in tumour size in the overall
population of evaluable patients (n¼25) treated with the triweekly
schedule. Data are largest response during study, irrespective of the time of
assessment. Notes: Patients with complete response (n¼1) or partial
response (n¼1) according to the WHO criteria are shown in red and blue
bars, respectively, while those with stable disease (SD, n¼6) or progressive
disease (PD, n¼17) are shown in grey and white bars, respectively. Four
patients with SD had tumour shrinkage, whereas two patients with SD did
not. Nine patients had PD in target lesions, while eight patients had PD in
non-target lesions.
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Figure 4 Kaplan–Meier curves of progression-free (red line) and overall
survival (blue line) in patients treated with the triweekly schedule (n¼27).
Vertical ticks denote censored observations.
048 1 2 1 6 2 0
0
20
40
60
80
100
OS
PFS
Time (months)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Figure 5 Kaplan–Meier curves of progression-free (red line) and overall
survival (blue line) in the cohort of 12 sorafenib-resistant patients, enrolled
in the triweekly schedule (n¼5) or weekly schedule (n¼7). Vertical ticks
denote censored observations.
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sorafenib in the Asia-Pacific study. The objective response rate was
however around 3% in both studies.
In conclusion, the evidence of preliminary antitumour activity
noted with NGR-hTNF in this study seems to deserve further
testing in advanced HCC. The mode of action, along with a
favourable tolerability profile characterised by the lack of drug-
related grade 3–4 toxicity, could also facilitate the incorporation of
NGR-hTNF into combination regimens for HCC patients.
Consistently, in preclinical models even low concentrations of
NGR-TNF were able to increase the activity of a variety of
chemotherapeutic agents (Curnis et al, 2002b; Sacchi et al, 2006).
These synergistic effects were deemed owing to the tumour
capillary network damage, thereby increasing the chemotherapy
uptake. Moreover, a safe clinical toxicity profile was reported
combining NGR-hTNF with a chemotherapeutic agent used in
HCC such as doxorubicin (Gregorc et al, 2009). In addition, there
is a strong mechanistic rationale for an enhanced activity of
vascular-damaging agents when combined with antiangiogenic
drugs (Shaked et al, 2006).
Finally, given the drawbacks inherent in interpreting results
from single-arm trial in a heterogeneous malignancy such as
HCC, a more suitable approach for further evaluation might be a
randomised study design by using time-to-event as the primary
end point. The potential clinical benefit of NGR-hTNF, therefore,
needs to be prospectively assessed against the best investi-
gator’s option in sorafenib-pretreated patients with advanced-
stage HCC.
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